Back to News
Market Impact: 0.05

Drivers over 70 to face eye tests every three years

Regulation & LegislationTransportation & LogisticsAutomotive & EVHealthcare & BiotechElections & Domestic PoliticsLegal & Litigation
Drivers over 70 to face eye tests every three years

The UK will require drivers aged 70 and over to undergo vision checks every three years under a new road safety strategy that also proposes lowering England's drink‑driving limit to Scotland's level and adding penalty points for not wearing seatbelts. The move—prompted by figures showing nearly one in four car drivers killed in 2024 were aged 70+ and by a coroner's criticism of the DVLA's self‑reporting system—may modestly boost demand for optometry services and has targeted implications for insurers and mobility providers serving older drivers.

Analysis

Market structure: Mandatory tri‑annual vision checks for drivers 70+ disproportionately benefit optical services, eyewear manufacturers and ophthalmic device makers (incremental UK testing demand could lift private optician revenues by ~1–3% over 12–24 months; global lens/frame sellers get a small but sticky recurring revenue benefit). Motor insurers should see a modest reduction in claims frequency concentrated in the 70+ cohort—back‑of‑envelope: a 10–20% decline in crashes for that cohort translates to ~1–2% lower motor claims industrywide over 2–4 years, boosting combined ratios slightly. Public transport, community mobility services and mobility tech providers are secondary beneficiaries if licence surrender rises. Risk assessment: Tail risks include stricter enforcement or faster rollouts that create rapid demand shock for surgeries (cataract/AMD) and capacity bottlenecks in optometry, or conversely political pushback that stalls implementation (material if delayed >12 months). Short‑term (days) market impact is negligible; short‑term (weeks–months) depends on regulatory details and funding announcements; long‑term (1–3 years) drives recurring testing, referrals and device/surgical volumes. Hidden dependencies: NHS funding for extra tests, optometrist headcount, and DVLA enforcement rules determine capture rates; litigation or data/privacy rules around reporting could change costs. trade implications: Tactical long exposure to large, liquid eyewear/ophthalmic names with diversified revenue and pricing power (see tickers below) makes sense; use conservative sizing (1–3% positions) and option structures to limit downside while keeping upside to a 12–24 month policy adoption cycle. Insurer longs should be small, event‑driven trades sized to expected claims tail (0.5–2% portfolio). Monitor 30–60 day policy rollout milestones to scale positions. contrarian angles: Consensus assumes only modest demand uplift because NHS tests are already free for >60s, but enforcement of licensing is the marginal catalyst that converts latent need into paid optical upgrades and surgical referrals—this can compound over 2–3 years. Risk is underinvestment in optometry capacity; if capacity proves constrained, listed device makers (ALC/COO) and global frame/lens consolidators could capture outsized pricing power. If the policy is watered down or self‑reporting remains dominant, the bullish case collapses quickly; size positions to that binary outcome.